Enterra therapy is an implanted device that sends mild electrical pulses to the stomach to reduce chronic nausea and vomiting caused by gastroparesis. Made by Medtronic, the system works like a pacemaker for the stomach, delivering small bursts of energy to the stomach wall when medications have failed to control symptoms. The FDA approved it in 2000 specifically for adults aged 18 to 70 with drug-resistant gastroparesis caused by diabetes or unknown origins.
How the Device Works
The Enterra system uses high-frequency, low-energy electrical stimulation. Two thin wires (leads) are surgically placed into the muscle wall of the stomach, and each delivers short rectangular pulses lasting about 330 microseconds at a frequency of 14 cycles per second. These pulses fire in brief bursts lasting a tenth of a second, repeating every five seconds. The stimulation doesn’t restore normal stomach contractions the way a cardiac pacemaker restores heart rhythm. Instead, it appears to reduce the signals that trigger nausea and vomiting, though the exact biological pathway isn’t fully understood.
The leads connect to a small pulse generator, roughly the size of a stopwatch, that sits in a pocket just beneath the skin of the lower abdomen, typically between the rib cage and the belt line. The generator runs continuously on a sealed internal battery. When the battery eventually weakens, a minor surgery replaces the generator while the original leads stay in place, assuming they’re still functioning properly.
What the Surgery Involves
Implantation can be done as an open procedure through a small abdominal incision or laparoscopically through several tiny incisions. The surgeon places electrode-tipped leads into the stomach’s muscle layer, tunnels the lead wires under the skin to the lower abdomen, and connects them to the pulse generator in its subcutaneous pocket. Most patients stay one night in the hospital and go home the next day, though a longer stay is sometimes necessary depending on other health conditions or complications.
Evidence for Symptom Relief
A randomized crossover trial published in Gastroenterology tested Enterra by comparing periods with the device switched on versus off in the same patients. Vomiting scores were significantly better during the “on” periods, with a median score of 2 (on a scale where 0 means daily vomiting and 4 means none) compared to a median of 1 when the device was off. This improvement held for both diabetic and nondiabetic patients, and it applied regardless of whether gastric emptying was delayed or normal.
Those numbers reflect meaningful but modest relief. Enterra doesn’t eliminate symptoms entirely for most people. A systematic review in Gastroenterology Research and Practice found that it improves nausea, vomiting, and overall quality of life while helping patients maintain better nutritional status. For someone who has been vomiting daily despite medications, going from constant vomiting to intermittent episodes can be life-changing, even if it’s not a cure.
FDA Approval and What It Means
Enterra holds a Humanitarian Device Exemption (HDE) from the FDA, which is different from standard device approval. An HDE is granted for devices that treat conditions affecting fewer than 8,000 people per year in the U.S., meaning the patient population is too small to run the large-scale clinical trials typically required. The approved annual distribution number for Enterra is capped at 8,000 devices. This regulatory pathway reflects the rarity of severe, drug-resistant gastroparesis rather than a safety concern, but it does mean the device hasn’t gone through the same level of clinical trial scrutiny as a fully approved product.
Risks and Complications
The most commonly reported complications involve the hardware itself. Lead migration, where the electrode tips shift out of their original position in the stomach wall, can reduce the therapy’s effectiveness and may require a second surgery to reposition them. Infection at the site of the pulse generator pocket is another known risk, sometimes requiring removal of the device to clear the infection. Bowel obstruction has also been reported, though it’s uncommon.
As with any abdominal surgery, there are general surgical risks including pain at the incision site, bleeding, and reactions to anesthesia. The device may also interfere with implanted cardiac defibrillators or pacemakers, so people with those devices need careful evaluation before implantation.
Living With the Device
Once the device is in place and programmed, it runs continuously without any action from you. Your doctor can adjust the stimulation settings externally during office visits. Day-to-day life is mostly normal, but there are a few important restrictions.
MRI scans are off the table entirely. The magnetic fields can damage the device and potentially cause injury. Similarly, certain types of physical therapy that use deep heat, including shortwave diathermy, microwave diathermy, and therapeutic ultrasound, are permanently off-limits anywhere on the body.
Security screening devices at airports, libraries, and retail stores can interact with the stimulator. You’ll receive a medical identification card to carry with you. The general guidance is to walk through the center of any screening gate at a normal pace without stopping or leaning against it, and to request a manual pat-down search when possible.
Safety during pregnancy has not been established. The concern is that side effects of stimulation could pose risks to an unborn child, so reliable birth control is recommended for women of childbearing age who have the device.
Who Is a Candidate
Enterra is specifically indicated for people whose nausea and vomiting from gastroparesis hasn’t responded to medications. Both diabetic gastroparesis and idiopathic gastroparesis (where no clear cause has been identified) qualify. The approved age range is 18 to 70. Candidates have typically tried multiple anti-nausea and motility drugs without adequate relief and may be losing weight, becoming dehydrated, or struggling to maintain nutrition because of relentless vomiting. It’s considered a later-line option after dietary changes and drug therapy have been exhausted.